14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MRNA vs BNTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, BioNTech SE American Depositary Share (BNTX) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas BNTX carries 41.8/100 (SELL) at $80.96 (7.0x Forward P/E, -55.5% operating margin).
Growth vs. Quality Trade-Off: BNTX earns the overall head-to-head edge with a stronger Unified Composite Score (41.8/100 SELL vs. MRNA 40.3/100 SELL) and 0.77β · 30% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although BNTX compares more favorably head-to-head, both MRNA (40.3/100 SELL) and BNTX (41.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile BNTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs BNTX. Trailing 12-month operating profitability (MRNA -80.8% vs BNTX -55.5%) and valuation multiples (MRNA 23.0x vs BNTX 7.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $20.2B market capitalization and -55.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MRNA vs BNTX Key Questions & Quantitative Answers
As of Nov 20, 2026, BioNTech SE American Depositary Share (BNTX) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas BNTX carries 41.8/100 (SELL) at $80.96 (7.0x Forward P/E, -55.5% operating margin). Growth vs. Quality Trade-Off: BNTX earns the overall head-to-head edge with a stronger Unified Composite Score (41.8/100 SELL vs. MRNA 40.3/100 SELL) and 0.77β · 30% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although BNTX compares more favorably head-to-head, both MRNA (40.3/100 SELL) and BNTX (41.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile BNTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with BNTX at -15.1% YoY revenue growth and -43.2% YoY earnings growth on $2.42B TTM revenue (76.7% gross margin, -55.5% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus $2.42B for BNTX. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BNTX.
BNTX screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas BNTX trades at 7.0x Forward P/E, 7.0x Trailing P/E, 0.05x PEG, and 8.3x EV/Revenue (-42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus BNTX (-8.1% ROE) capital efficiency.
In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, BNTX carries 41.9% implied volatility (76th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.77β · 30% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.